{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:53:58Z","timestamp":1794693238695,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7015-18"],"award-info":[{"award-number":["7015-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7015-18"],"award-info":[{"award-number":["7015-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1113133"],"award-info":[{"award-number":["GNT1113133"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41418-022-00977-2","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T08:57:23Z","timestamp":1648198643000},"page":"1335-1348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-2788","authenticated-orcid":false,"given":"Diane","family":"Moujalled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Southon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-6674","authenticated-orcid":false,"given":"Kerstin","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-7665","authenticated-orcid":false,"given":"Francine","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-2715","authenticated-orcid":false,"given":"Misty R.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong","family":"Nhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1454-9566","authenticated-orcid":false,"given":"Melissa X.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7101-1925","authenticated-orcid":false,"given":"Ruth M.","family":"Kluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-8147","authenticated-orcid":false,"given":"Guillaume","family":"Lessene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grabow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9069","authenticated-orcid":false,"given":"Ashley I.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-4891","authenticated-orcid":false,"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41578-019-0135-y","volume":"4","author":"KJ Wolf","year":"2019","unstructured":"Wolf KJ, Chen J, Coombes J, Aghi MK, Kumar S. Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nat Rev Mater. 2019;4:651\u201368.","journal-title":"Nat Rev Mater"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1073\/pnas.1219747110","volume":"110","author":"A Sottoriva","year":"2013","unstructured":"Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013;110:4009\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/biomedicines9030324","volume":"9","author":"JP Fisher","year":"2021","unstructured":"Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9:324\u201336.","journal-title":"Biomedicines"},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"977_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/s41418-021-00814-y","volume":"28","author":"D Moujalled","year":"2021","unstructured":"Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28:2029\u201344.","journal-title":"Cell Death Differ"},{"key":"977_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.cdd.4400998","volume":"9","author":"H Puthalakath","year":"2002","unstructured":"Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002;9:505\u201312.","journal-title":"Cell Death Differ"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-cancerbio-030419-033510","volume":"4","author":"GL Kelly","year":"2020","unstructured":"Kelly GL, Strasser A. Toward targeting antiapoptotic MCL-1 for cancer therapy. Annu Rev Cancer Biol. 2020;4:299\u2013313.","journal-title":"Annu Rev Cancer Biol"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"977_CR9","first-page":"787490","volume":"2011","author":"A Cimini","year":"2011","unstructured":"Cimini A, Ippoliti R. Innovative Therapies against human glioblastoma multiforme. ISRN Oncol. 2011;2011:787490.","journal-title":"ISRN Oncol"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1471-4159.2003.01522.x","volume":"84","author":"Z Jiang","year":"2003","unstructured":"Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem. 2003;84:273\u201381.","journal-title":"J Neurochem"},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.18632\/oncotarget.1154","volume":"4","author":"U Liwak","year":"2013","unstructured":"Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, et al. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget. 2013;4:1365\u201372.","journal-title":"Oncotarget."},{"key":"977_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41420-019-0199-x","volume":"5","author":"M Milani","year":"2019","unstructured":"Milani M, Beckett AJ, Al-Zebeeby A, Luo X, Prior IA, Cohen GM, et al. DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis. Cell Death Discov. 2019;5:117.","journal-title":"Cell Death Discov"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature."},{"key":"977_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nchembio.1246","volume":"9","author":"G Lessene","year":"2013","unstructured":"Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013;9:390\u20137.","journal-title":"Nat Chem Biol"},{"key":"977_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"977_CR16","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.3390\/cancers12113353","volume":"12","author":"VS Lin","year":"2020","unstructured":"Lin VS, Xu ZF, Huang DCS, Thijssen R. BH3 mimetics for the treatment of B-cell malignancies-insights and lessons from the clinic. Cancers. 2020;12:3353\u201376.","journal-title":"Cancers"},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582\u201397.","journal-title":"Cancer Discov"},{"key":"977_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"key":"977_CR20","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/febs.13472","volume":"283","author":"JT Opferman","year":"2016","unstructured":"Opferman JT. Attacking cancer\u2019s Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J. 2016;283:2661\u201375.","journal-title":"FEBS J"},{"key":"977_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1568-3","volume":"10","author":"EF Lee","year":"2019","unstructured":"Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10:342.","journal-title":"Cell Death Dis"},{"key":"977_CR22","first-page":"100756","volume":"22","author":"SF Abdul Rahman","year":"2020","unstructured":"Abdul Rahman SF, Muniandy K, Soo YK, Tiew EYH, Tan KX, Bates TE, et al. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophys Rep. 2020;22:100756.","journal-title":"Biochem Biophys Rep"},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.celrep.2016.02.039","volume":"14","author":"S Grabow","year":"2016","unstructured":"Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing Pro-B cells to apoptosis. Cell Rep. 2016;14:2337\u201347.","journal-title":"Cell Rep"},{"key":"977_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/hep.23126","volume":"50","author":"H Hikita","year":"2009","unstructured":"Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217\u201326.","journal-title":"Hepatology."},{"key":"977_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34:879\u201391.","journal-title":"Cancer Cell"},{"key":"977_CR26","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell."},{"key":"977_CR27","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/scd.2017.0123","volume":"26","author":"MD Polewski","year":"2017","unstructured":"Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev. 2017;26:1236\u201346.","journal-title":"Stem Cells Dev"},{"key":"977_CR28","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3892\/or.2015.3712","volume":"33","author":"L Chen","year":"2015","unstructured":"Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-gamma-lyase function. Oncol Rep. 2015;33:1465\u201374.","journal-title":"Oncol Rep"},{"key":"977_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM. et al.Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model.Cell Chem Biol. 2019;26:623\u201333. e9.","journal-title":"Cell Chem Biol"},{"key":"977_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"977_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nature12147","volume":"498","author":"SR Floyd","year":"2013","unstructured":"Floyd SR, Pacold ME, Huang Q, Clarke SM, Lam FC, Cannell IG, et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013;498:246\u201350.","journal-title":"Nature."},{"key":"977_CR32","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.18632\/oncotarget.6275","volume":"7","author":"GQ Li","year":"2016","unstructured":"Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget. 2016;7:2462\u201374.","journal-title":"Oncotarget."},{"key":"977_CR33","doi-asserted-by":"publisher","first-page":"29558","DOI":"10.18632\/oncotarget.16365","volume":"8","author":"CT Ishida","year":"2017","unstructured":"Ishida CT, Bianchetti E, Shu C, Halatsch ME, Westhoff MA, Karpel-Massler G, et al. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. Oncotarget. 2017;8:29558\u201373.","journal-title":"Oncotarget."},{"key":"977_CR34","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-12-3066","volume":"19","author":"Z Cheng","year":"2013","unstructured":"Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013;19:1748\u201359.","journal-title":"Clin Cancer Res"},{"key":"977_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04315-4","volume":"9","author":"FC Lam","year":"2018","unstructured":"Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9:1991.","journal-title":"Nat Commun"},{"key":"977_CR36","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"977_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharm. 2012;5:102\u201314.","journal-title":"Curr Mol Pharm"},{"key":"977_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0300060513501753","volume":"42","author":"W Shen","year":"2014","unstructured":"Shen W, Hu JA, Zheng JS. Mechanism of temozolomide-induced antitumour effects on glioma cells. J Int Med Res. 2014;42:164\u201372.","journal-title":"J Int Med Res"},{"key":"977_CR39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071\u201380.","journal-title":"Cell Death Differ"},{"key":"977_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.biochem.69.1.217","volume":"69","author":"A Strasser","year":"2000","unstructured":"Strasser A, O\u2019Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217\u201345.","journal-title":"Annu Rev Biochem"},{"key":"977_CR41","first-page":"1483","volume":"63","author":"H Yamaguchi","year":"2003","unstructured":"Yamaguchi H, Bhalla K, Wang HG. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac\/Diablo and Omi\/HtrA2 release from mitochondria. Cancer Res. 2003;63:1483\u20139.","journal-title":"Cancer Res"},{"key":"977_CR42","doi-asserted-by":"publisher","first-page":"e1283","DOI":"10.1002\/cti2.1317","volume":"10","author":"RC Abbott","year":"2021","unstructured":"Abbott RC, Verdon DJ, Gracey FM, Hughes-Parry HE, Iliopoulos M, Watson KA, et al. Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma. Clin Transl Immunology 2021;10:e1283.","journal-title":"Clin Transl Immunology"},{"key":"977_CR43","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell."},{"key":"977_CR44","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"977_CR45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/1541-7786.MCR-16-0028","volume":"14","author":"MD Polewski","year":"2016","unstructured":"Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. Increased expression of system xc- in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol Cancer Res. 2016;14:1229\u201342.","journal-title":"Mol Cancer Res"},{"key":"977_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","volume":"16","author":"K Aldape","year":"2019","unstructured":"Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16:509\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"977_CR47","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.","journal-title":"Sci Transl Med"},{"key":"977_CR48","doi-asserted-by":"publisher","first-page":"118987","DOI":"10.1016\/j.bbamcr.2021.118987","volume":"1868","author":"S Kehr","year":"2021","unstructured":"Kehr S, Vogler M. It\u2019s time to die: BH3 mimetics in solid tumors. Biochim Biophys Acta Mol Cell Res. 2021;1868:118987.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"977_CR49","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"977_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O van Tellingen","year":"2015","unstructured":"van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1\u201312.","journal-title":"Drug Resist Updat"},{"key":"977_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20:184\u201391.","journal-title":"Neuro Oncol"},{"key":"977_CR52","doi-asserted-by":"publisher","first-page":"e1054549","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2:e1054549.","journal-title":"Mol Cell Oncol"},{"key":"977_CR53","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","volume":"15","author":"PW Gout","year":"2001","unstructured":"Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633\u201340.","journal-title":"Leukemia."},{"key":"977_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14844","volume":"8","author":"DS Liu","year":"2017","unstructured":"Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, et al. Inhibiting the system xC(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun. 2017;8:14844.","journal-title":"Nat Commun"},{"key":"977_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19213-4","volume":"8","author":"M Sato","year":"2018","unstructured":"Sato M, Kusumi R, Hamashima S, Kobayashi S, Sasaki S, Komiyama Y, et al. The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin\u2019s cytotoxicity in cancer cells. Sci Rep. 2018;8:968.","journal-title":"Sci Rep"},{"key":"977_CR56","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.1158\/0008-5472.CAN-04-4267","volume":"65","author":"Y Huang","year":"2005","unstructured":"Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65:7446\u201354.","journal-title":"Cancer Res"},{"key":"977_CR57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2020","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2020;12:599\u2013620.","journal-title":"Protein Cell"},{"key":"977_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57\u201362.","journal-title":"Nature."},{"key":"977_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00304-3","volume":"10","author":"X Yang","year":"2021","unstructured":"Yang X, Liu J, Wang C, Cheng KK, Xu H, Li Q, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021;10:15.","journal-title":"Oncogenesis."},{"key":"977_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.65","volume":"6","author":"Z Fan","year":"2017","unstructured":"Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6:e371.","journal-title":"Oncogenesis."},{"key":"977_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-29","volume":"6","author":"PA Robe","year":"2006","unstructured":"Robe PA, Martin D, Albert A, Deprez M, Chariot A, Bours V. A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer. 2006;6:29.","journal-title":"BMC Cancer"},{"key":"977_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-372","volume":"9","author":"PA Robe","year":"2009","unstructured":"Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1\/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9:372.","journal-title":"BMC Cancer"},{"key":"977_CR63","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1016\/j.bmcl.2015.07.018","volume":"25","author":"MH Larraufie","year":"2015","unstructured":"Larraufie MH, Yang WS, Jiang E, Thomas AG, Slusher BS, Stockwell BR. Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. Bioorg Med Chem Lett. 2015;25:4787\u201392.","journal-title":"Bioorg Med Chem Lett"},{"key":"977_CR64","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593:586\u201390.","journal-title":"Nature."},{"key":"977_CR65","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O\u2019Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422\u201332.","journal-title":"Cell Rep"},{"key":"977_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07309-4","volume":"9","author":"HS Chin","year":"2018","unstructured":"Chin HS, Li MX, Tan IKL, Ninnis RL, Reljic B, Scicluna K, et al. VDAC2 enables BAX to mediate apoptosis and limit tumor development. Nat Commun. 2018;9:4976.","journal-title":"Nat Commun"},{"key":"977_CR67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bph.14881","volume":"177","author":"A Southon","year":"2020","unstructured":"Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Cu(II) (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br J Pharm. 2020;177:656\u201367.","journal-title":"Br J Pharm"}],"container-title":["Cell Death & Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00977-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00977-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00977-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T03:07:10Z","timestamp":1657854430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00977-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1038\/s41418-022-00977-2","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"23 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DM, ES., KB, FK, MI, RSC, MRJ, DN, ZW, MXS, RMK, GL, SG and AS are or were employees of WEHI which receives royalties from AbbVie and Genentech from the sale of Venetoclax. GL and AS are collaborating with and have received funding from Servier for work on the development of MCL-1-specific BH3 mimetic drugs for cancer therapy. AIB is a shareholder in Alterity Ltd, Cogstate Ltd and Mesoblast Ltd. He is a paid consultant fee for, and has a profit share interest in Collaborative Medicinal Development Pty Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}